TORECAN Drug Patent Profile
✉ Email this page to a colleague
When do Torecan patents expire, and what generic alternatives are available?
Torecan is a drug marketed by Novartis and is included in three NDAs.
The generic ingredient in TORECAN is thiethylperazine maleate. There are two drug master file entries for this compound. Additional details are available on the thiethylperazine maleate profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for TORECAN?
- What are the global sales for TORECAN?
- What is Average Wholesale Price for TORECAN?
Summary for TORECAN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 3 |
| Raw Ingredient (Bulk) Api Vendors: | 86 |
| Clinical Trials: | 1 |
| Patent Applications: | 3,779 |
| DailyMed Link: | TORECAN at DailyMed |
Recent Clinical Trials for TORECAN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of Rijeka | N/A |
US Patents and Regulatory Information for TORECAN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | TORECAN | thiethylperazine malate | INJECTABLE;INJECTION | 012754-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Novartis | TORECAN | thiethylperazine maleate | SUPPOSITORY;RECTAL | 013247-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Novartis | TORECAN | thiethylperazine maleate | TABLET;ORAL | 012753-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
